This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
NEJM.org
nejm.org
did:plc:mgwrki6irihfcatu2v347soc
In two trials involving patients with chronic spontaneous urticaria, remibrutinib led to significantly greater reductions than placebo in itching and hives at week 12. Full results of the REMIX-1 and REMIX-2 trials: nej.md/41uQD07
#MedSky #DermSky
2025-03-09T13:36:05.154Z